Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
K
Kadry, Hossam
Pfizer Inc.
(
S-084
)
Population pharmacokinetic modeling of anti-B7H4 antibody-drug conjugate (SGN-B7H4V) in patients with advanced solid tumors from phase 1 study
Hossam Kadry
Favorite
Kang, Dongwoo
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, United States
(
T-084
)
Population Pharmacokinetics of Deutetrabenazine in Asian Individuals
Dongwoo Kang
Favorite
Kang, Jia
Metrum Research Group, USA
(
M-115
)
Dosage modifications in exposure-response analyses of oncology drug development: the brigimadlin case study
Jia Kang
Favorite
Karamitsou, Venetia
ESQlabs
(
T-015
)
A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury
Venetia Karamitsou
Favorite
(
T-016
)
Reducing Animal Use in Toxicological Research through Open-Source Individualized (PB)PK/QST Modeling: A Case Study with Phenobarbital in Dogs
Venetia Karamitsou
Favorite
Karas, Spinel
Pfizer Inc
(
M-012
)
Population pharmacokinetics and pharmacodynamics analysis of PF-07328948, a branched-chain ketoacid dehydrogenase kinase inhibitor, in healthy participants
Spinel Karas
Favorite
Kawakatsu, Sonoko
Gilead Sciences, Inc.
(
M-094
)
Population Pharmacokinetic Analysis of Zimberelimab in Patients with Solid Tumors
Sonoko Kawakatsu
Favorite
Kennard, Benjamin
Allucent
(
S-059
)
Population Pharmacokinetic, Exposure-Response, and Time-To-Event Analyses of Probenecid in Symptomatic, Non-Hospitalized Patients with COVID-19
Benjamin Kennard
Favorite
Kim, Jaeyeon
Novartis
(
S-045
)
Model-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization
Jaeyeon Kim
Favorite
Kim, Kyeongmin
The Ohio State University
(
S-112
)
Sparse Sampling Strategies for Monoclonal Antibody Pharmacokinetics: Evaluating Estimation Methods for Reliable Clearance Assessment
Kyeongmin Kim
Favorite
Kim, Se Jin
University at Buffalo, SUNY
(
T-086
)
PK/PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer
Se Jin Kim
Favorite
Knab, Timothy
Metrum Research Group
(
S-095
)
A Julia Package for Traceable and Reproducible Models in Quantitative Systems Pharmacology
Timothy Knab
Favorite
Knöchel, Jane
InSilicoTrials Technologies S.p.A., Trieste, Italy.
(
M-042
)
Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application
Jane Knöchel
Favorite
(
M-044
)
A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Jane Knöchel
Favorite
Kosinski, Luke
Critical Path Institute
(
T-058
)
Modeling Huntington’s disease progression utilizing the Huntington’s disease integrated staging system
Luke Kosinski
Favorite
Krzyzanski, Wojciech
University at Buffalo
(
M-027
)
Implementation of Distributed Delay Differential Equations in RADAU5 and RADAR5
Wojciech Krzyzanski
Favorite
(
T-014
)
ACS-SIMULATOR: A Shiny Application for Guiding Antenatal Corticosteroid Administration in Pregnant Women
Wojciech Krzyzanski
Favorite
Kulesza, Alexander
ESQlabs GmbH
(
M-021
)
An open-source and modular workflow for prototyping bispecific T-cell engager safety modules and integrating them into PBPK models
Alexander Kulesza
Favorite
(
M-022
)
A multi-model strategy in R to address cytopenia
Alexander Kulesza
Favorite
(
M-023
)
Towards uncertainty assessment-based acceptability thresholds for model validation?
Alexander Kulesza
Favorite
Kumbale, Carla
Pfizer
(
T-064
)
Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity
Carla Kumbale
Favorite
Kuruvilla, Denison
Genentech
(
T-046
)
Population Pharmacokinetics of Subcutaneous Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Denison Kuruvilla
Favorite
